{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Growth+Factors+Laboratory+Testing", "query": { "intervention": "Growth Factors Laboratory Testing" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Growth+Factors+Laboratory+Testing&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T06:56:02.228Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00134420", "title": "Growth Hormone and Chromosome 18q- and Abnormal Growth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Loss of Chromosome 18q", "Growth Hormone Deficiency" ], "interventions": [ { "name": "Nutropin AQ", "type": "DRUG" }, { "name": "Arginine and Clonidine Stimulation Testing", "type": "PROCEDURE" }, { "name": "Growth Factors Laboratory Testing", "type": "PROCEDURE" }, { "name": "Neuropsychological Testing", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 20, "start_date": "2001-02", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134420" }, { "nct_id": "NCT00985036", "title": "Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioma", "Meningioma" ], "interventions": [ { "name": "Blood test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Marquette General Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2009-09", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-04-24", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 1, "location_summary": "Marquette, Michigan", "locations": [ { "city": "Marquette", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00985036" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT02130869", "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Lymphoma", "High-risk Tumor" ], "interventions": [ { "name": "CD133+ selected autologous stem cell infusion", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "hu14.18K322A", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Haploidentical natural killer cell infusion", "type": "DEVICE" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Etoposide phosphate", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 8, "start_date": "2014-10-10", "completion_date": "2017-12-20", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02130869" }, { "nct_id": "NCT02298959", "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Colorectal Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Renal Cell Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Recurrent Melanoma", "Recurrent Renal Cell Carcinoma", "Refractory Melanoma", "Refractory Renal Cell Carcinoma", "Sarcoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-04-08", "completion_date": "2027-01-20", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 7, "location_summary": "Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298959" }, { "nct_id": "NCT07582172", "title": "Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Complex Karyotype", "Myelodysplastic Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Recurrent Secondary Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic Syndrome", "Refractory Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "BIOLOGICAL" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total Marrow and Lymphoid Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2027-04-05", "completion_date": "2029-04-05", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07582172" }, { "nct_id": "NCT03078036", "title": "International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Germline BRCA Test (blood)", "type": "GENETIC" }, { "name": "FoundationOne Dx Genomic Profile (archival Tumour Specimen)", "type": "GENETIC" }, { "name": "Follow-up", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 873, "start_date": "2017-03-13", "completion_date": "2019-05-20", "has_results": false, "last_update_posted_date": "2020-05-20", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 14, "location_summary": "Santa Barbara, California • Denver, Colorado • Hialeah, Florida + 10 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Denton", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078036" }, { "nct_id": "NCT02503722", "title": "Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-03-23", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Tampa, Florida", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02503722" }, { "nct_id": "NCT04144023", "title": "A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Ductal Carcinoma In Situ" ], "interventions": [ { "name": "Granulocyte-Macrophage Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Multi-epitope HER2 Peptide Vaccine H2NVAC", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2019-06-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04144023" }, { "nct_id": "NCT06160206", "title": "Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma", "Recurrent WHO Grade 4 Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2024-10-02", "completion_date": "2030-11-30", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-06T06:56:02.228Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160206" } ] }